Baek Jiwon, Doh Sang Hee, Chung Sung Kun
a Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine , The Catholic University of Korea , Seoul , Korea.
b Department of Ophthalmology and Visual Science, St. Paul's Hospital, College of Medicine , The Catholic University of Korea , Seoul , Korea.
Curr Eye Res. 2016 Oct;41(10):1281-1285. doi: 10.3109/02713683.2015.1122813. Epub 2016 Apr 6.
To evaluate the effectiveness of 3% diquafosol tetrasodium for treating dry eye after cataract surgery.
Among patients who underwent bilateral cataract surgery, 34, who met the diagnostic criteria for dry eye syndrome 1 week postoperatively, were enrolled. Patients were randomly assigned to receive 3.0% diquafosol tetrasodium ophthalmic solution in one eye and 0.9% saline in the other eye four times daily for 8 weeks. Dry eye severity was measured at 1, 5, and 9 postoperative weeks using the Schirmer 1 test (SIT), tear film breakup time (TBUT), and fluorescein corneal staining. tear meniscus height (TMH), tear meniscus depth (TMD), and tear meniscus area (TMA) measured using Fourier-domain optical coherence tomography and symptom questionnaire scores.
TBUT and corneal staining significantly improved 8 weeks postoperatively in eyes treated with 3.0% diquafosol tetrasodium (p < 0.01, p < 0.01) and were better than normal saline-treated eyes (p < 0.01, p < 0.01). SIT did not improve (p = 0.26). TMH, TMD, and TMA did not improve at 4 and 8 weeks. All symptom questionnaire scores improved in eyes treated with 3.0% diquafosol tetrasodium (all p < 0.01).
The 3.0% diquafosol tetrasodium treatment improved tear film stability and subjective symptoms of dry eye after cataract surgery. Increased mucin production as a result of diquafosol treatment may have caused these results.
评估3%双醋瑞因四钠治疗白内障术后干眼的有效性。
在接受双侧白内障手术的患者中，纳入34例术后1周符合干眼综合征诊断标准的患者。患者被随机分配，一只眼睛每日4次接受3.0%双醋瑞因四钠滴眼液治疗，另一只眼睛每日4次接受0.9%生理盐水治疗，持续8周。术后第1、5和9周，使用Schirmer 1试验（SIT）、泪膜破裂时间（TBUT）和荧光素角膜染色测量干眼严重程度。使用傅里叶域光学相干断层扫描测量泪液半月皱襞高度（TMH）、泪液半月皱襞深度（TMD）和泪液半月皱襞面积（TMA），并评估症状问卷评分。
术后8周，接受3.0%双醋瑞因四钠治疗的眼睛的TBUT和角膜染色有显著改善（p<0.01，p<0.01），且优于接受生理盐水治疗的眼睛（p<0.01，p<0.01）。SIT没有改善（p=0.26）。4周和8周时，TMH、TMD和TMA没有改善。接受3.0%双醋瑞因四钠治疗的眼睛的所有症状问卷评分均有所改善（所有p<0.01）。
3.0%双醋瑞因四钠治疗改善了白内障术后泪膜稳定性和干眼主观症状。双醋瑞因治疗导致的黏蛋白分泌增加可能是这些结果的原因。
